Abstract 200P
Background
Malignant Mixed Mullerian Tumor (MMMT) also known as carcinosarcoma is considered as a rare aggressive biphasic tumor with carcinomatous and sarcomatous elements found in postmenopausal women, uterus being the most common site, followed by cervix, vagina, and rarely adnexa or vulva. It usually presents at an advanced stage and lacks specific treatment guidelines requiring a multimodality approach with surgery and chemoradiation (CTRT) for better prognosis & outcomes. The aim was to study the patterns of failure and overall survival in patients treated with different modalities.
Methods
An observational analysis of 82 patients from the year 2015-2019 was done including demographic data such as age and ECOG status. The patients were staged based on the FIGO 2019 system after imaging and histopathological examination. The different treatment regimens with surgery and lymph node dissection (LND), CTRT used as definitive or adjuvant therapy was noted. This study shows the impact of surgery and CTRT on overall survival (OS), progression free survival (PFS) and disease specific survival (DSS) according to stage and type of treatment. We conducted Kaplan-Meier method with log-rank tests for comparison of prognostic factors with survival and Cox proportional hazard model for both univariate and multivariate analysis considering p values <0.05 to be statistically significant. The median follow-up period was 35 months (4-76).
Results
The OS rate was 37.8% with a median of 28 months (95% CI: 22.3-33.6), a better OS was present by 34 months (95% CI: 17.18-50.81) in patients who had received adjuvant CTRT, 12 months (95% CI: 9-15) with definitive CTRT, while 7 months (95% CI: 4-10) with only surgery. There was a statistically significant improvement (p-0.001) in overall survival rate by 65.5% for those who underwent both LND with radiation. The PFS rate was 58.5% with a median of 47 months; stage I-IIIC with both surgery and CTRT had a better PFS and DSS by 64.3% and 46.4% respectively (p-0.001).
Conclusions
Patients receiving stagewise combined modality approach with both surgery and CTRT for management had a significantly better OS, PFS and DSS in comparison to with only single mode of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03